Skip to main content
. 2021 Aug 18;12:666837. doi: 10.3389/fmicb.2021.666837

TABLE 3.

Effects of different feeding modes on immune indices of Black Fattening Goat (n = 10).

Treatment Period Ig(A) (μ g/mL) Ig(G) (μ g/mL) Ig(M) (μ g/mL) TNF-α (pg/mL) IL-1β (pg/mL) IL-6 (pg/mL) IL-10 (pg/mL)
Grazing (G) Day 0 181.89 ± 20.45a 6.6 ± 0.8a 837.09 ± 193.81 181.63 ± 22.95 70.32 ± 13.75 144.98 ± 22.42 29.4 ± 7.59
Day 53 190.64 ± 28.47 8.29 ± 0.77at 1,155.78 ± 206.71t 141.49 ± 22.3t 54.67 ± 11.38t 89.99 ± 10.8t 42.57 ± 6.72t
Day 100 238.09 ± 22.53at 8.92 ± 0.66at 1,409.79 ± 234.9t 107.74 ± 16.25t 31.41 ± 11.69t 77.59 ± 17.1t 50.64 ± 5.88t
Barn feeding (BF) Day 0 132.21 ± 17.59 5.09 ± 0.52 780.56 ± 142.63 175.51 ± 25.51 74 ± 12.12 133.41 ± 29.71 29.46 ± 6.4
Day 53 159.96 ± 31.75 7.14 ± 0.6t 1,119.44 ± 116.86t 145.67 ± 24.3t 45.96 ± 7.74t 103.24 ± 25.64t 48.91 ± 9.06t
Day 100 196.2 ± 25.39t 7.62 ± 1.12t 1,449.73 ± 211.17t 109.02 ± 16.58t 33.52 ± 13.14t 81.27 ± 15.85t 51.49 ± 8.46t
Barn feeding + probiotics (BF + P) Day 0 160 ± 29.61 6.82 ± 0.99a 790.35 ± 209.57 181.6 ± 14.97 71.62 ± 16.74 141.87 ± 25.81 32.36 ± 4.67
Day 53 193.43 ± 18.37at 7.72 ± 0.95t 1,172.4 ± 164.32t 149.15 ± 14t 48.09 ± 12.96t 102.48 ± 14.18t 46.39 ± 8.79t
Day 100 233.29 ± 27.19at 8.98 ± 0.53at 1,464.88 ± 247.67t 100.26 ± 17.93t 27.52 ± 12.88t 74.82 ± 15.34t 54.32 ± 8.02t
Overall analysis HF 1 1 1 0.978 1 1 0.971
Treatment F, P 21.185, <0.001 24.141, <0.001 0.141, 0.869 0.001, 0.999 0.424,0.659 0.071,0.932 1.282,0.295
Period F, P 47.069, <0.001 62.157, <0.001 69.238, <0.001 96.699, <0.001 73.963, <0.001 80.239, <0.001 75.866, <0.001
Interaction F, P 0.688, 0.604 1.316, 0.286 0.223, 0.924 0.577, 0.680 0.765, 0.553 1.321, 0.275 0.718, 0.584

The overall analysis is two-way repeated measures ANOVA. Bonferroni multiple correction was used for the comparison among treatments and periods, the letter “a” indicates the comparison with the barn feeding (BF) group at the same time point (P < 0.05), and the letter “t” was used for comparison with day 0 of the same treatment (P < 0.05).